Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
UK biopharmaceutical company Arecor has joined with Scottish animal health charity GALVmed to create a vaccine to combat two major diseases of livestock in the developing world.
US animal health company Zoetis has increased its canine influenza virus (CIV) vaccine portfolio with a new combination product.
Developing a bacteriophage platform technology for use in animal health has taken Polish company Proteon Pharmaceuticals a decade to master. Chief operating officer Mathew Tebeau talks to Animal Pharm analyst Malcolm Flanagan about the firm's past and future.
The European Medicines Agency (EMA) has adopted a positive opinion for a swine vaccine from Zoetis.
Managing human behaviour, enhancing international cooperation and conducting more scientific research have been pinpointed as crucial elements to eradicate African Swine fever (ASF) from the EU.
UK firm ECO Animal Health has seen a strong 8% increase in revenues during the first half of its fiscal 2017.
Researchers in Cambodia said the south west of the country is embedded with dangerous highly pathogenic avian influenza (HPAI).
Aquaculture's leading vaccine specialist Pharmaq has opened a new manufacturing facility to produce viral antigens for use in fish vaccines.
One possible path for Elanco next year could see it become a standalone entity. While this option will have some benefits for Elanco, it would see the firm lose the R&D capabilities its parent company has to offer. Animal Pharm editor Joseph Harvey takes a closer look at the potential situation.
US livestock vaccines speciliast AgriLabs has developed master seeds for adenovirus vectored foot-and-mouth disease (FMD) vaccines.
Boehringer Ingelheim Vetmedica (BIVI) is pre-empting an increased demand for veterinary vaccines by spending $80 million on expanding its existing facilities in Athens, Georgia and St Joseph, Missouri.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.